Tuesday, April 17, 2012
Morphotek Inc., of Exton, Pa., a subsidiary of Eisai Inc., began a Phase II trial of MORAb-004 for colorectal cancer. The randomized, double-blind, placebo-controlled trial will evaluate safety and efficacy of single-agent MORAb-004 with supportive care for progression-free survival in patients with chemo-refractory metastatic colorectal cancer. Secondary endpoints include overall survival and identification of efficacy biomarkers.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.